Circular RNA PVT1 Regulates Cell Proliferation, Migration, and Apoptosis by Stabilizing c-Myc and Downstream Target CXCR4 Expression in Acute Myeloid Leukemia

Objective: This study aimed to investigate the role and mechanism of circular RNA PVT1 (circPVT1) in patients with acute myeloid leukemia (AML). Materials and Methods: The expression of circPVT1 in 23 patients with de novo AML (not acute promyelocytic leukemia, not APL) and cell lines were detected by RT-qPCR. Loss of function assays were carried out to explore the influence of silenced circPVT1 on the proliferation, migration, and apoptosis in the THP-1 cell line. CCK-8 assays, trans-well assays, and annexin V/PI staining assays were performed to assess proliferation, migration, and apoptosis, respectively. Results: CircPVT1 was highly expressed in AML patients and myeloid cell lines compared to healthy controls. Higher expression of circPVT1 was related to shorter overall survival (OS) and relapse-free survival (RFS) in AML patients. Cell viability and migration were inhibited and apoptosis was increased when circPVT1 was knocked down in THP-1 cells. Knockdown of circPVT1 resulted in marked suppression of c-Myc protein with no significant change in mRNA levels. We also found that circPVT1 knockdown markedly increased the phosphorylation of c-Myc Thr-58, which was responsible for c-Myc degradation. Silencing of c-Myc caused a significant decrease in CXCR4 mRNA and protein expression, whereas the overexpression of c-Myc caused the opposite result, suggesting that CXCR4 is a target molecule of c-Myc. Finally, we found that overexpression of c-Myc could partially reverse circPVT1 knockdown-induced anti-tumor effects on THP-1 cells in vitro. Conclusion: Our findings showed that circPVT1 was highly expressed in AML patients and was related to shorter OS and RFS. CircPVT1 may exert an oncogenic effect in THP-1 cells by stabilizing c-Myc protein expression and downstream target CXCR4 expression. These data indicate that circPVT1 may be a promising therapeutic target for AML.

[1]  R. Yao,et al.  Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability , 2022, Cell communication and signaling : CCS.

[2]  [Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)]. , 2021, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[3]  K. Laribi,et al.  Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review , 2021, Annals of Hematology.

[4]  Tao Chen,et al.  The role of circular RNA plasmacytoma variant translocation 1 as a biomarker for prognostication of acute myeloid leukemia , 2021, Hematology.

[5]  Youguo Chen,et al.  Circular PVT1 regulates cell proliferation and invasion via miR-149-5p/FOXM1 axis in ovarian cancer , 2021, Journal of Cancer.

[6]  Q. Wen,et al.  Long non-coding RNA MALAT1 modulate cell migration, proliferation and apoptosis by sponging microRNA-146a to regulate CXCR4 expression in acute myeloid leukemia , 2020, Hematology.

[7]  M. Hirst,et al.  MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus. , 2020, Blood.

[8]  E. Wang,et al.  Novel therapies for AML: a round-up for clinicians , 2020, Expert review of clinical pharmacology.

[9]  M. Bøgsted,et al.  Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000–2016: a Danish population‐based study , 2020, British journal of haematology.

[10]  A. Gartel,et al.  Therapeutic Vulnerabilities of Transcription Factors in AML , 2020, Molecular Cancer Therapeutics.

[11]  G. Martinelli,et al.  Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin , 2020, Molecular Cancer.

[12]  Sarah Crunkhorn.  Epigenetic therapy prevents AML , 2020, Nature Reviews Drug Discovery.

[13]  Xiaofeng Sun,et al.  Circular RNA PVT1 enhances cell proliferation but inhibits apoptosis through sponging microRNA‐149 in epithelial ovarian cancer , 2020, The journal of obstetrics and gynaecology research.

[14]  K. Majidzadeh-A,et al.  Circular RNA; a new biomarker for breast cancer: A systematic review , 2020, Journal of cellular physiology.

[15]  Hiroyuki Takahashi,et al.  The expression of MYC is strongly dependent on the circular PVT1 expression in pure Gleason pattern 4 of prostatic cancer , 2020, Medical Molecular Morphology.

[16]  G. Calin,et al.  Long Non-coding RNAs in Myeloid Malignancies , 2019, Front. Oncol..

[17]  Sebastian Kadener,et al.  Past, present, and future of circRNAs , 2019, The EMBO journal.

[18]  W. Elayat,et al.  The prognostic significance of the long non-coding RNAs "CCAT1, PVT1" in t(8;21) associated Acute Myeloid Leukemia. , 2019, Gene.

[19]  Z. Zeng,et al.  Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis , 2019, Cellular and Molecular Life Sciences.

[20]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[21]  R. Davis,et al.  BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. , 2019, The Journal of clinical investigation.

[22]  R. Levine,et al.  Genetic and epigenetic determinants of AML pathogenesis. , 2019, Seminars in hematology.

[23]  Xiao-jun Huang,et al.  New approaches in allogenic transplantation in AML. , 2019, Seminars in hematology.

[24]  Z. Estrov,et al.  MYC protein expression is an important prognostic factor in acute myeloid leukemia , 2019, Leukemia & lymphoma.

[25]  M. Ahmadvand,et al.  Expression Analysis of PVT1, CCDC26, and CCAT1 Long Noncoding RNAs in Acute Myeloid Leukemia Patients. , 2018, Genetic testing and molecular biomarkers.

[26]  Xiang Li,et al.  The Biogenesis, Functions, and Challenges of Circular RNAs. , 2018, Molecular cell.

[27]  Tianxin Lin,et al.  Circular RNA, a novel marker for cancer determination (Review). , 2018, International journal of molecular medicine.

[28]  Y. Qu,et al.  Cumulative Evidence for Relationships Between 8q24 Variants and Prostate Cancer , 2018, Front. Physiol..

[29]  A. Chinnaiyan,et al.  Competing for enhancers: PVT1 fine-tunes MYC expression , 2018, Cell Research.

[30]  I. Berindan‐Neagoe,et al.  A miRNAs profile evolution of triple negative breast cancer cells in the presence of a possible adjuvant therapy and senescence inducer. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[31]  Z. Ge,et al.  Circular RNA PVT1 expression and its roles in acute lymphoblastic leukemia. , 2018, Epigenomics.

[32]  Hong Yang,et al.  Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases , 2018, Cellular Physiology and Biochemistry.

[33]  Wei Zhao,et al.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. , 2018, Cell systems.

[34]  M. Severgnini,et al.  MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences , 2018, Leukemia.

[35]  I. Berindan‐Neagoe,et al.  A Looking-Glass of Non-Coding RNAs in Oral Cancer , 2017, International journal of molecular sciences.

[36]  P. Luo,et al.  lncRNA PVT1 in cancer: A review and meta-analysis. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[37]  L. Penn,et al.  MYC Deregulation in Primary Human Cancers , 2017, Genes.

[38]  Jie Chen,et al.  Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. , 2017, Cancer letters.

[39]  Ji-hua Zhong,et al.  Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. , 2016, Experimental and therapeutic medicine.

[40]  Shaohua Chen,et al.  Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia , 2015, Journal of Hematology & Oncology.

[41]  G. Macino,et al.  PVT1: A Rising Star among Oncogenic Long Noncoding RNAs , 2015, BioMed research international.

[42]  T. Hampton,et al.  The Cancer Genome Atlas , 2020, Indian Journal of Medical and Paediatric Oncology.

[43]  F. Rassool,et al.  Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment , 2019, Advances in cancer research.

[44]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.